Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham maintained a Buy rating on the stock and has a $115.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Matson has given his Buy rating due to a combination of factors related to Boston Scientific’s strategic decisions and growth potential. The company has decided to discontinue its ACURATE neo2 and ACURATE Prime transcatheter aortic valve replacements, a move influenced by regulatory challenges and diminishing sales prospects. Despite this, Boston Scientific is poised to mitigate the impact through its other promising products, notably FARAPULSE and WATCHMAN, which are expected to sustain strong growth.
Furthermore, Matson highlights the potential of the CHAMPION trial results, anticipated in the first half of 2026, as a significant growth catalyst. If successful, these results could lead to a first-line indication for WATCHMAN, expanded Medicare coverage, and a notable increase in WATCHMAN’s market presence. Consequently, any short-term weakness in Boston Scientific’s stock is viewed as an opportunity for investors, given the company’s robust growth drivers and reaffirmed financial guidance.
In another report released yesterday, Raymond James also maintained a Buy rating on the stock with a $121.00 price target.